Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
EV/EBIT
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Enterprise Value to EBIT (EV/EBIT) ratio compares a company`s total enterprise value to its earnings before interest and taxes. It shows how much investors are paying for each dollar of the company`s earnings, including both equity and debt.
Valuation Scenarios
If EV/EBIT returns to its 3-Year Average (23.8), the stock would be worth ¥13.66 (4% downside from current price).
| Scenario | EV/EBIT Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 24.8 | ¥14.27 |
0%
|
| 3-Year Average | 23.8 | ¥13.66 |
-4%
|
| 5-Year Average | 24.6 | ¥14.12 |
-1%
|
| Industry Average | 23.4 | ¥13.47 |
-6%
|
| Country Average | 28.9 | ¥16.6 |
+16%
|
Forward EV/EBIT
Today’s price vs future ebit
| Today's Enterprise Value | EBIT | Forward EV/EBIT | ||
|---|---|---|---|---|
|
¥10B
|
/ |
Jan 2026
¥390.8m
|
= |
|
|
¥10B
|
/ |
Dec 2026
¥686.7m
|
= |
|
|
¥10B
|
/ |
Dec 2027
¥710.9m
|
= |
|
Forward EV/EBIT shows whether today’s EV/EBIT still looks high or low once future ebit are taken into account.
Peer Comparison
| Market Cap | EV/EBIT | P/E | ||||
|---|---|---|---|---|---|---|
| CN |
|
Shandong Xinhua Pharmaceutical Co Ltd
SZSE:000756
|
9.8B CNY | 24.8 | 34 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
820.3B USD | 28.7 | 39.7 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
542.6B USD | 21.2 | 25.8 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 13.4 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.7B GBP | 21.9 | 28.1 | |
| CH |
|
Novartis AG
SIX:NOVN
|
218.2B CHF | 15.6 | 19.6 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
272.8B USD | 11.4 | 14.9 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | 970 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.2T DKK | 9.9 | 11.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.3B USD | 10.1 | 19.6 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
116.3B USD | 8.8 | 16.5 |
Market Distribution
| Min | 0 |
| 30th Percentile | 16.6 |
| Median | 28.9 |
| 70th Percentile | 52.9 |
| Max | 49 021 |
Other Multiples
Shandong Xinhua Pharmaceutical Co Ltd
Glance View
In the industrious province of Shandong, China, Shandong Xinhua Pharmaceutical Co. Ltd. emerges as a notable player in the pharmaceutical landscape. Established in 1943, the company has grown into a comprehensive pharmaceutical enterprise with a significant presence both domestically and internationally. At its core, Shandong Xinhua is devoted to the research, development, and manufacture of active pharmaceutical ingredients (APIs), finished dosages, and chemical intermediates. The firm's strength lies in its diverse range of products, with pain management and anti-infectives being standout categories. Their strategic focus on innovation is evident in their state-of-the-art R&D facilities, which fuel continuous product development, ensuring they meet high regulatory standards and cater to evolving market demands. The journey of Shandong Xinhua is one of strategic evolution, with a steadfast commitment to quality and sustainability. This narrative is reflected in their robust revenue streams derived from both domestic sales and the lucrative export markets across over 50 countries. The company's business model hinges on creating value through efficient manufacturing processes and leveraging economies of scale, which enhances their competitive edge in the global market. With an eye on future growth, they've also been investing in digitalization to streamline operations and enhance productivity. As the pharmaceutical sector continues to expand, Shandong Xinhua Pharmaceutical Co. Ltd. is poised to capitalize on emerging opportunities, underpinned by its solid foundation and innovative thrust.